icon-folder.gif   Conference Reports for NATAP  
  66th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 13-17 2015
Back grey_arrow_rt.gif
The Association of Sustained Virological Response and Mortality After Interferon-based Therapy for Chronic Hepatitis C (HCV) in a Large U.S. Community-based Health Care Delivery System....SVR Reduces Mortality a Lot/Treating Early Before Cirrhosis Reduced Mortality vs in Cirrhotics
  Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Lisa M. Nyberg1, Xia Li2, Su-Jau Yang2, Kevin Chiang3, T. Craig Cheetham2, Susan Caparosa2, Jose Pio2, Zobair M. Younossi 4 , Anders H. Nyberg1
from Jules: of interest in Table 1 and in Table 2 below is the difference in mortality between cirrhotics vs non-cirrhotics among those who achieve SVR (24.7% vs 0); Treating before cirrhosis results in 4 times lower mortality rate: all-cause mortality was 8.1% vs 2.1% in cirrhotics vs non-cirrhotics in Table 1.
SVR rates in patients with and without cirrhosis were 38.7% and 56.4%, respectively
The total mortality rate during the study period in those who received treatment was 11.6%
There was a reduction in mortality in those who achieved SVR in both cirrhotics and non-cirrhotics (Chi-square p-value <0.0001)
Mortality was markedly higher in patients with cirrhosis who did not achieve SVR (23.7%) vs cirrhotics who did achieve SVR (8.1%), nearly a 3-fold increase (Chi-square p-value <0.0001)
Even in non-cirrhotics, there was a marked increase in mortality in those who did not achieve SVR. Mortality in this group was approx 2.5-fold increase compared to those who achieved SVR, at 5.3% and 2.1% respectively.
Of note, liver related mortality is ZERO in non-cirrhotics who achieve SVR